OR2H2 Antibody

What is OR2H2 and where is it expressed in human tissues?

OR2H2 is an olfactory receptor belonging to the G protein-coupled receptor family. Though originally identified in olfactory tissues, OR2H2 shows ectopic expression in multiple non-olfactory tissues. Transcriptomic analyses have confirmed its expression in:

• Human thyroid tissue (both healthy and malignant)

• Vaginal epithelial cells (VK2/E6E7)

• Liver cells (HepG2)

• Skeletal muscle tissue

• Various cell lines including K562, 293, MCF-7, and LNCap

Notably, immunocytochemistry studies have demonstrated that OR2H2 localizes to both the cell membrane and perinuclear regions of the cytosol, with approximately 13% of the OR2H2 signal overlapping with plasma membrane markers .

What are the common applications for OR2H2 antibodies in research?

Based on validated protocols, OR2H2 antibodies are primarily used in the following applications:

• Western Blot (WB): Used at a 1:2000 dilution to detect OR2H2 protein, with predicted band size of 35 kDa. Immunoblotting has revealed higher molecular weight bands (~75 kDa) in some applications, potentially indicating dimerization .

• Flow Cytometry (FC): Utilized at 1:10-1:50 dilution ranges for detecting OR2H2 protein in cells like HepG2 .

• Immunocytochemistry/Immunofluorescence: For cellular localization studies and co-localization with other markers .

• Expression Analysis: For comparing OR2H2 expression levels between healthy and pathological tissues .

What is the structure and molecular characteristics of commercial OR2H2 antibodies?

Commercial OR2H2 antibodies are typically:

• Clonality: Most validated OR2H2 antibodies are polyclonal antibodies raised in rabbit .

• Isotype: Commonly rabbit IgG .

• Immunogen: Generated using KLH-conjugated synthetic peptides, typically from the C-terminal region (amino acids 276-302) of human OR2H2 .

• Molecular Weight: The calculated molecular weight of the target protein is approximately 34,763 Da, though observed bands can vary based on post-translational modifications .

• Target Specificity: Reactive specifically to human OR2H2 in validated applications .

How can researchers validate the specificity of OR2H2 antibodies in their experiments?

Validating OR2H2 antibody specificity requires a multi-faceted approach:

• Knockout Validation: Following recent standardized approaches for antibody characterization, knockout (KO) cell lines should be used to confirm specificity. This is particularly important given the challenges in antibody specificity that have been estimated to waste approximately $1 billion in research funding annually .

• Multiple Antibody Comparison: Test antibodies targeting different epitopes of OR2H2. For example, using both N-terminal and C-terminal antibodies as performed in some studies to validate expression .

• Positive Controls: Include tissues or cell lines with confirmed OR2H2 expression (e.g., HepG2 cells) .

• Western Blot Profile Analysis: OR2H2 antibodies typically detect a band at approximately 35 kDa, but may also detect higher molecular weight bands (75 kDa) that could represent dimers or post-translationally modified forms .

• Cross-Reactivity Testing: Test for potential cross-reactivity with closely related olfactory receptors, particularly paralogues such as OR13D1 .

What are the optimal experimental conditions for Western blot using OR2H2 antibodies?

Based on validated protocols, the following conditions yield optimal results:

Western Blot Protocol for OR2H2 Detection:

• Sample Preparation:

  • Prepare whole cell lysates or tissue homogenates

  • Load 20 μg protein per lane for optimal detection

• Blocking Conditions:

  • 5% non-fat dry milk (NFDM) in TBST for 1 hour at room temperature

• Primary Antibody:

  • 1:2000 dilution of anti-OR2H2 antibody in blocking buffer

  • Incubate overnight at 4°C

• Secondary Antibody:

  • Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1:10000 dilution

  • Incubate for 1 hour at room temperature

• Detection:

  • Enhanced chemiluminescence (ECL) substrate

  • Expected band size: 35 kDa (primary band)

  • Potential observation of 75 kDa band (possible dimer)

How do OR2H2 antibodies perform across different tissue types and what challenges might researchers encounter?

OR2H2 antibody performance varies across tissues, with several challenges to consider:

Tissue-Specific Performance:

• Thyroid Tissue: OR2H2 expression is detectable in both healthy and malignant thyroid cells, with significantly higher mRNA expression in healthy surrounding thyroid tissue compared to carcinoma tissues .

• Neural Tissue: Detection may be challenging due to variable expression levels.

• Cell Lines: Strong detection in HepG2, with varying signals in K562, 293, MCF-7, and LNCap cell lines .

Common Challenges:

• Expression Level Variability: OR2H2 expression varies dramatically across tissues and disease states, requiring optimization of detection protocols.

• Post-Translational Modifications: Multiple bands may appear due to glycosylation or other modifications common in membrane proteins.

• Subcellular Localization: OR2H2 localizes to both membrane and cytoplasmic compartments, potentially requiring different fixation protocols for complete detection .

• mRNA-Protein Correlation Discrepancies: Some studies have observed discordance between mRNA and protein levels (e.g., in Alzheimer's disease samples), suggesting complex post-transcriptional regulation .

How can researchers investigate OR2H2 signaling pathways using specific antibodies?

Investigating OR2H2 signaling requires combining antibody-based detection with functional assays:

• Pathway Identification Strategy:

  • Use OR2H2 antibodies for co-immunoprecipitation to identify interacting proteins

  • Combine with phospho-specific antibodies to detect activation of downstream effectors

• Established Signaling Pathways:

  • Calcium Signaling: OR2H2 activation has been shown to increase intracellular calcium

  • cAMP Signaling: Activation of OR2H2 affects cAMP concentrations

  • Downstream Effectors: Adenylate cyclase (AC) and phosphoinositide phospholipase C (PLC) are involved in OR2H2 signaling

  • CAMKKβ–AMPK–Autophagy Axis: OR2H2 has been implicated in activating this pathway in some cell types

• Functional Readouts:

  • Migration assays

  • Proliferation assays

  • Invasion assays

  • These have all shown responses to OR2H2 activation, particularly in thyroid cells

What approaches can be used to resolve contradictory results when using OR2H2 antibodies?

When faced with contradictory results, consider these methodological approaches:

• Multiple Antibody Validation:

  • Test antibodies targeting different epitopes of OR2H2

  • Compare results from different antibody clones/manufacturers

• Expression Analysis Cross-Validation:

  • Compare protein detection (antibody-based) with mRNA expression (RT-PCR, qPCR)

  • Transcriptomic data from public databases can provide additional reference points

  • Note that discordance between mRNA and protein levels has been observed in some studies

• Controls for Post-Transcriptional Regulation:

  • Consider the following mechanisms that might explain discrepancies:

    • MicroRNA involvement

    • Translation-inhibitory proteins

    • Ribosome sequestration

    • mRNA structural modifications

    • Chemical modifications (e.g., N6 adenosine methylation)

    • Alternative mRNA splicing

• Subcellular Fractionation:

  • OR2H2 localizes to different cellular compartments

  • Separate membrane and cytosolic fractions to resolve apparent contradictions in detection

• Disease State Consideration:

  • OR2H2 expression changes in disease states (e.g., decreased in thyroid cancer )

  • Consider disease progression timing (e.g., early vs. late Alzheimer's disease stages)

What is the current understanding of OR2H2 involvement in disease processes?

Recent research has revealed several disease associations:

• Thyroid Cancer:

  • OR2H2 mRNA expression is significantly higher in healthy thyroid tissue compared to carcinoma tissues

  • OR2H2 activation affects migration, proliferation, and invasion in both healthy and malignant thyroid cells

• Cellular Aging:

  • OR2H2 activation has been shown to activate the CAMKKβ–AMPK–Autophagy signaling axis

  • This activation impedes cellular aging processes

  • OR2H2 has demonstrated a senolytic effect by inducing apoptosis in senescent cells

• Neurodegenerative Disorders:

  • While the specific OR2H2 role has not been extensively studied in neurodegenerative contexts, research on related olfactory receptors (e.g., OR2K2) suggests potential involvement in processes like autophagy that are relevant to neurodegenerative diseases

How do different fixation and permeabilization protocols affect OR2H2 antibody performance in immunofluorescence?

Optimizing fixation and permeabilization is crucial for accurate OR2H2 detection:

Recommended Protocol for OR2H2 Immunofluorescence:

• Fixation: 4% paraformaldehyde for 15-20 minutes at room temperature

• Permeabilization: 0.1-0.2% Triton X-100 for 10 minutes

• Blocking: 5% normal serum (matching secondary antibody host) with 0.1% Triton X-100

• Primary Antibody: Incubate overnight at 4°C

• Secondary Antibody: Fluorophore-conjugated, incubated for 1-2 hours at room temperature

• Counterstaining: DAPI for nuclear visualization

• Mounting: Anti-fade mounting medium

Performance Considerations:

• Over-fixation may mask OR2H2 epitopes, particularly for antibodies targeting the C-terminal region

• Membrane localization requires careful permeabilization to maintain structural integrity while allowing antibody access

• Co-localization studies with membrane markers (e.g., phalloidin) can help confirm proper membrane preservation

What are the emerging technologies improving OR2H2 antibody specificity for research applications?

Several advanced approaches are enhancing antibody specificity:

• Computational Design and Active Learning:

  • Machine learning models can predict antibody-antigen binding and improve specificity

  • Active learning approaches reduce the number of required antigen variants by up to 35%

  • These computational approaches can be applied to optimize OR2H2 antibody design

• Open Science Collaboration Platforms:

  • Initiatives like YCharOS (Antibody Characterization through Open Science) are standardizing antibody characterization across manufacturers

  • These platforms test antibodies across applications including immunoblotting, immunoprecipitation, and immunofluorescence

  • Similar approaches could be applied specifically to OR2H2 antibodies

• Biophysics-Informed Models:

  • Recent advances in biophysics-informed models allow the design of antibodies with customized specificity profiles

  • These models can disentangle multiple binding modes associated with specific ligands

  • Application to OR2H2 antibodies could improve their discriminatory abilities against closely related olfactory receptors

• Knockout Cell Validation:

  • Systematic testing using knockout cell lines provides definitive validation of antibody specificity

  • This approach is particularly important for olfactory receptors, which share significant sequence homology

How can researchers analyze contradictory data between OR2H2 protein and mRNA expression levels?

Discrepancies between protein and mRNA expression are common with olfactory receptors and require systematic analysis:

• Documentation of Discrepancies:

  • Studies have observed opposite trends in OR2H2 mRNA and protein levels in some conditions

  • Examples include increased mRNA with decreased protein in early disease stages

• Potential Explanatory Mechanisms:

  • Protein Degradation: Consider autophagy or proteasomal degradation pathways

  • Compensatory Transcription: Increased mRNA production in response to protein degradation

  • Post-Transcriptional Regulation: microRNAs, RNA-binding proteins, etc.

  • Protein Stability Issues: Half-life differences between normal and disease states

• Experimental Approaches to Resolve Discrepancies:

  • Protein Degradation Inhibitors: Use autophagy inhibitors (e.g., chloroquine) or proteasome inhibitors (e.g., MG132)

  • Pulse-Chase Experiments: To measure protein turnover rates

  • Polysome Profiling: To assess translation efficiency

  • mRNA Stability Assays: To measure mRNA half-life using actinomycin D

  • Co-localization with Degradation Markers: As demonstrated with autophagy markers LC3 and p62

• Analytical Framework:

  Analysis Level	Techniques	Expected Outcomes	Potential Discrepancies
  Transcription	RT-PCR, qPCR, RNA-seq	mRNA expression levels	Increased/decreased vs control
  Translation	Polysome profiling, Ribosome profiling	Translation efficiency	May not correlate with mRNA levels
  Protein Expression	Western blot, ELISA, Mass spectrometry	Protein levels	May show opposite trend to mRNA
  Protein Degradation	Co-IP with ubiquitin, autophagy markers	Degradation pathway activity	Explains low protein despite high mRNA
  Localization	Immunofluorescence, subcellular fractionation	Protein distribution	Redistribution without total level change

This systematic approach provides a framework for reconciling apparently contradictory data about OR2H2 expression.

What are the promising research avenues for OR2H2 antibodies in disease diagnostics and therapeutics?

Based on current findings, several promising research directions emerge:

• Thyroid Cancer Biomarkers:

  • Differential expression of OR2H2 between healthy and cancerous thyroid tissue suggests potential diagnostic applications

  • Further research could establish OR2H2 as a diagnostic marker or therapeutic target

• Anti-Aging Applications:

  • OR2H2's role in activating the CAMKKβ–AMPK–Autophagy signaling axis and impeding cellular aging suggests therapeutic potential

  • Development of OR2H2 agonists could offer novel approaches to combat age-related cellular dysfunction

• Neurodegenerative Disease Research:

  • Exploring the relationship between OR2H2 and autophagy pathways in neural tissues could provide insights into neurodegenerative processes

  • Antibody-based detection could help map expression changes during disease progression

• Pharmaceutical Development:

  • Understanding OR2H2 signaling pathways could guide development of small molecule modulators

  • OR2H2-targeted approaches might offer tissue-specific therapeutic options due to its differential expression patterns

How might advances in antibody engineering improve current limitations of OR2H2 antibodies?

Emerging antibody engineering approaches offer solutions to current limitations:

• Enhanced Specificity:

  • Biophysics-informed models can guide the design of antibodies with customized specificity profiles

  • This approach could reduce cross-reactivity with other olfactory receptors

• Improved Detection Sensitivity:

  • Fragment-based approaches and recombinant antibody technology could improve detection of low-abundance OR2H2

  • Single-domain antibodies might access epitopes unavailable to conventional antibodies

• Subcellular Targeting:

  • Engineering antibodies to target specific subcellular locations of OR2H2 (membrane vs. cytoplasmic)

  • Development of compartment-specific detection systems

• Multiplex Detection Systems:

  • Creating antibody panels that simultaneously detect OR2H2 along with its signaling partners

  • Integration with proximity ligation assays to detect specific protein-protein interactions